Significant ETF Inflows: VONG, ABBV, HD, RCL

Written by Emily J. Thompson, Senior Investment Analyst

ABBV-0.08%

HD+0.27%

RCL-0.82%

Source: NASDAQ.COM

Updated: Sep 10 2025

0mins

Source: NASDAQ.COM

VONG Share Price Analysis: VONG's current share price is $117.93, close to its 52-week high of $117.95, with a low of $79.395 in the same period.
ETFs Trading Dynamics: ETFs function like stocks, trading in "units" that can be created or destroyed based on investor demand, impacting the underlying assets when there are significant inflows or outflows.

ABBV

$217.925+Infinity%1D

Analyst Views on ABBV

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

22 Analyst Rating

15 Buy

7 Hold

0 Sell

Moderate Buy

Current: 218.110

Low

218.00

Averages

253.26

High

289.00

Current: 218.110

Low

218.00

Averages

253.26

High

289.00

Berenberg

Buy

maintain

$270 -> $275

2026-01-20

New

Reason

Berenberg

Price Target

$270 -> $275

AI Analysis

2026-01-20

New

maintain

Buy

Reason

Berenberg raised the firm's price target on AbbVie to $275 from $270 and keeps a Buy rating on the shares. The firm upped its forecasts for AbbVie's Skyrizi and Rinvoq citing an "exceptional" growth outlook.

Wedbush

Outperform

upgrade

$80 -> $147

2026-01-09

Reason

Wedbush

Price Target

$80 -> $147

2026-01-09

upgrade

Outperform

Reason

Wedbush raised the firm's price target on Revolution Medicines (RVMD) to $147 from $80 and keeps an Outperform rating on the shares. The firm notes that several news outlets have reported that Revolution is in talks with multiple parties to be acquired, including AbbVie (ABBV) and most recently Merck (MRK) who reported a valuation of between $28B and $32B was being discussed, but a deal was maybe not imminent and could take a few weeks to be finalized. Given the evolving news cycle, Wedbush is assuming the Financial Times report on Merck is likely accurate.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV

Unlock Now

Wolfe Research

Outperform -> Peer Perform

downgrade

2026-01-08

Reason

Wolfe Research

Price Target

2026-01-08

downgrade

Outperform -> Peer Perform

Reason

Wolfe Research downgraded AbbVie to Peer Perform from Outperform.

Wolfe Research

Outperform -> Peer Perform

downgrade

2026-01-08

Reason

Wolfe Research

Price Target

2026-01-08

downgrade

Outperform -> Peer Perform

Reason

Wolfe Research downgraded AbbVie to Peer Perform from Outperform without a price target. The firm believes the shares already reflect expectations for outperformance in Skyrizi and Rinvoq. Wolfe moves to the sidelines pending greater visibility on AbbVie's immunology and inflammation "encore" and competitive dynamics.

About ABBV

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.